Venmax Drugs and Pharmaceuticals share price
BSE: 531015Pharmaceuticals & BiotechnologySmall Cap
Venmax Drugs and Pharmaceuticals Ltd · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Aug 1995
Last close ₹14.00up ₹0.13 (0.94%)
Share price at the BSE close on 27 Oct 2026. Previous close ₹13.87.
27 Oct: open ₹15.00, high ₹15.00, low ₹13.40
52-week range of traded prices to 27 Oct 2026
₹12.71Low, 17 Sep 2026₹31.49High, 3 Dec 2025
- Under BSE's graded surveillance, stage 0, on the list for 26 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹16 Cr4,053rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Earlier quarters restated in the year
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Not shown: another business merged into the company on 30 Jun 2026, and the accounts this figure is made of do not include it yet. It returns once accounts of the company as it now is are filed. Price to book: how it is worked out
- Mergernew accounts awaited
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- Volume, BSEVolume. Shares traded on the last trading day. Volume in the glossary
- 2,586
Results
Standalone; ₹ crore.Venmax Drugs and Pharmaceuticals quarterly results
- Revenue growth, 12 monthsRevenue growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +385.7%
- Net profit growth, 12 monthsNet profit growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- –
Quarter to Jun 2026, against the quarter before
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹2.48 Crdown 37.13%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent. Net profit in the glossary
- ₹0.12 Crup 8.77%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 4.7%
Revenue by quarter
Peak revenue ₹3.94 Cr, quarter to Mar 2026; lowest ₹0.17 Cr, quarter to Sep 2024
Net profit by quarter, a loss in red
- Net profit
- Loss
A loss in 2 of the 8 quarters shown
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.17 | 0.20 | 0.33 | 1.21 | 1.32 | 1.55 | 3.94 | 2.48 |
| Net profit | −0.30 | −0.50 | 0.78 | 0.04 | 0.02 | 0.03 | 0.11 | 0.12 |
| Net margin | −177.7% | −248.6% | 233.8% | 3.1% | 1.8% | 2.1% | 2.7% | 4.7% |
Standalone. The last eight quarters. The latest is shaded.
Year to Mar 2026, against the year before
- RevenueRevenue. The pill is the change in revenue against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹8.02 Crup 894.04%
- Net profitNet profit. Under it, net profit in the year before. A change in per cent is not worked out where either period is a loss or nothing.
- ₹0.25 CrYear to Mar 2025: −₹0.01 Cr
- Net margin
- 3.1%
Revenue by year
Peak revenue ₹8.02 Cr, year to Mar 2026; lowest ₹0.00 Cr, year to Mar 2022
Net profit by year, a loss in red
- Net profit
- Loss
Back to profit in the year to Mar 2026, ₹0.25 CrA loss in 6 of the 10 years shown
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.38 | – | 0.15 | 0.47 | 0.17 | 0.00 | 0.00 | 0.00 | 0.81 | 8.02 |
| Net profit | −1.34 | −0.24 | −0.24 | −0.27 | −0.16 | 1.85 | 0.23 | 0.06 | −0.01 | 0.25 |
| Net margin | −347.9% | – | −158.7% | −57.9% | −96.8% | – | – | – | −1.3% | 3.1% |
Standalone. Years to March. The latest is shaded.
Business segments
In the year to Mar 2026 the company reports one business segment, Trading of Drug intermediaries, which carries all its revenue.
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −9.6% | – | – | 0.0% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth and the change in P/E are left empty where earnings per share at either end of the window was a loss or is not on record. Earnings growth over 1 year is on profit divided by shares in issue at both ends: the earnings per share stated for one end does not match that year's profit and share count.
Venmax Drugs and Pharmaceuticals competitors and peers
Pharmaceuticals, 216 listed companies, priced on 27 Oct 2026. The table lists the 8 companies closest to Venmax Drugs and Pharmaceuticals in market cap. 1 company in the table last traded before then: its row is priced on its last trade.Healthcare companies
Venmax Drugs and Pharmaceuticals is not on the chart: it has no P/E or return on equity today
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Centuple GlobalCENTUPLE | 20 | 16.42 | 9.82 | +4,540.6% | +1,281.3% | 94.1% | 22.8% | 0.00% |
 Span DivergentSDL | 17 | – | 1.17 | +171.7% | – | – | −24.0% | 0.00% |
 Colinz LaboratoriesCOLINZ | 17 | 6.22 | 1.73 | −8.4% | +484.3% | 28.7% | 1.7% | 0.00% |
 Star Source Multi TradeSTARSOURCE | 17 | – | 13.30 | – | – | −0.5% | −3.1% | 0.00% |
 Zenith Health CareZENITHHE | 16 | 101.10 | 2.18 | −9.3% | – | 2.2% | −1.2% | 0.00% |
| Mono PharmacareMONOPHARMA | 16 | 44.40 | 0.50 | −1.6% | −88.3% | 1.1% | – | 0.00% |
 Desh Rakshak AushdhalayaDESHRAK | 15 | 27.77 | 1.15 | −24.3% | – | 4.7% | 5.8% | 0.00% |
 Beryl DrugsBERLDRG | 12 | 19.29 | 1.22 | +8.3% | +169.1% | 6.4% | 3.1% | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Latest announcements
Routine notices left out.Venmax Drugs and Pharmaceuticals announcements
Oct 2026
Sep 2026
Venmax Drugs and Pharmaceuticals annual report, year to Mar 2026
Venmax Drugs and Pharmaceuticals share price by year
Each calendar year to 2025.Venmax Drugs and Pharmaceuticals share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 24.95 | +38.3% | 35.29 | 18.43 |
| 2024 | 18.04 | +331.6% | 18.04 | 6.58 |
| 2018 | 4.18 | +6.1% | 4.21 | 4.01 |
| 2017 | 3.94 | +63.5% | 4.18 | 2.35 |
| 2016 | 2.41 | −17.2% | 3.00 | 2.37 |
| 2015 | 2.91 | −24.8% | 8.39 | 2.37 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. 2024 is from its first session, 4 Dec 2024. The change in 2024 is on the close at the end of 2018, the last year before it with a trade. The close is the year's last trade for 2018 (19 Mar 2018) and 2016 (16 Dec 2016).
Recent sessions
The 9 trading days to 26 Oct 2026, as traded on BSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume |
|---|---|---|---|---|---|---|
| 26 Oct 2026 | 13.50 | 15.20 | 12.99 | 13.87 | 14.03 | 22,705 |
| 23 Oct 2026 | 13.52 | 14.80 | 13.52 | 14.48 | 14.50 | 7,037 |
| 22 Oct 2026 | 14.30 | 16.25 | 14.30 | 14.99 | 14.61 | 816 |
| 21 Oct 2026 | 13.50 | 14.40 | 13.50 | 14.30 | – | 6 |
| 19 Oct 2026 | 14.21 | 14.49 | 13.51 | 14.43 | 14.22 | 296 |
| 16 Oct 2026 | 14.50 | 14.50 | 14.50 | 14.50 | 14.50 | 121 |
| 15 Oct 2026 | 14.69 | 14.69 | 14.68 | 14.68 | 14.68 | 304 |
| 14 Oct 2026 | 15.02 | 16.00 | 14.36 | 14.69 | 15.28 | 3,929 |
| 13 Oct 2026 | 14.49 | 16.29 | 13.43 | 15.02 | 14.10 | 6,590 |
Prices in ₹ per share as traded, not adjusted.
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Share consolidation history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 4 Dec 2024 | Price move | – | Between two trading sessions the price moved by a fifth or more. No corporate action is on record. Not adjusted for. |
| 29 Jan 2009 | Share count change | – | The company changed its share count by an amount the filing does not state, so earlier prices are not shown. |
Where an event has no factor that can be worked out, the chart leaves out the closes before it. Any other event is noted and not adjusted for.
Company details
- BSE code
- 531015
- ISIN
- INE154G01022
- Industry
- Pharmaceuticals & Biotechnology
- Website
- www.venmaxdrugs.com
- CIN
- L24230TG1988PLC009102
- Corporate identity number, the registrar of companies' code for it
- Incorporated
- 1988
- Registered office
- Shed No.22, Plot No.84, Phase-1, IDA Cherlapally, Hyderabad 500051, Telangana
- Share registrar
- CIL Securities Ltd
- Keeps the register of shareholders and handles transfers and dividend payments